Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CV Therapeutics Again Declines Astellas $16 Per Share Purchase Offer

This article was originally published in The Pink Sheet Daily

Executive Summary

During its 2008 earnings call, biotech says Astellas offer was inadequate when first offered and even more so today.

You may also be interested in...



CVT And Gilead Look To Lock Out Astellas With Planned Merger

Market reaction was mixed but CV Therapeutics and Gilead threw a shock into the current pharma/biotech merger and acquisition frenzy as Gilead sought to trump Astellas' months-long bid to acquire CVT with its own bid of $20 per share. The deal's estimated total value is $1.4 billion

CVT And Gilead Look To Lock Out Astellas With Planned Merger

Market reaction was mixed but CV Therapeutics and Gilead threw a shock into the current pharma/biotech merger and acquisition frenzy as Gilead sought to trump Astellas' months-long bid to acquire CVT with its own bid of $20 per share. The deal's estimated total value is $1.4 billion

Thrust & Parry: CVT And Gilead Look To Lock Out Astellas With Planned Merger

Gilead’s surprise $20 per share bid tops Astellas’ $16 per share offer, highlights Gilead’s increasing focus on cardiovascular space.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel